PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35191353-0 2022 Comparison of Fluorescein Angiography Findings in Stage 3 Retinopathy of Prematurity in Zone II Treated With or Without Anti-VEGF. Fluorescein 14-25 vascular endothelial growth factor A Homo sapiens 125-129 11148600-8 2000 RESULTS: In the high-dose VEGF-injected eye, fluorescein angiography showed intense retinal micro-vascular leakage. Fluorescein 45-56 vascular endothelial growth factor A Homo sapiens 26-30 8942877-6 1996 RESULTS: All six bioactive VEGF-injected eyes developed dilated, tortuous retinal vessels that leaked fluorescein. Fluorescein 102-113 vascular endothelial growth factor A Homo sapiens 27-31 8694732-6 1996 RESULTS: All 5 bioactive VEGF-injected eyes developed neovascularization with dilated and tortuous iris vessels that leaked fluorescein. Fluorescein 124-135 vascular endothelial growth factor A Homo sapiens 25-29 34803132-0 2022 A NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY: RECOVERY STUDY. Fluorescein 128-139 vascular endothelial growth factor A Homo sapiens 47-51 34803132-1 2022 PURPOSE: To quantify changes of the retinal vascular bed area (RVBA) in mm2 on stereographically projected ultra-wide field (UWF) fluorescein angiography (FA) images by in eyes with proliferative diabetic retinopathy (PDR) following anti-vascular endothelial growth factor (VEGF) injection. Fluorescein 130-141 vascular endothelial growth factor A Homo sapiens 238-272 34803132-1 2022 PURPOSE: To quantify changes of the retinal vascular bed area (RVBA) in mm2 on stereographically projected ultra-wide field (UWF) fluorescein angiography (FA) images by in eyes with proliferative diabetic retinopathy (PDR) following anti-vascular endothelial growth factor (VEGF) injection. Fluorescein 130-141 vascular endothelial growth factor A Homo sapiens 274-278 35191353-1 2022 PURPOSE: To define late-stage fluorescein angiography (FA) findings in patients who received anti-vascular endothelial growth factor (VEGF) agents (intravitreal bevacizumab or aflibercept) as a treatment for stage 3 retinopathy of prematurity (ROP) in zone II. Fluorescein 30-41 vascular endothelial growth factor A Homo sapiens 98-132 35191353-1 2022 PURPOSE: To define late-stage fluorescein angiography (FA) findings in patients who received anti-vascular endothelial growth factor (VEGF) agents (intravitreal bevacizumab or aflibercept) as a treatment for stage 3 retinopathy of prematurity (ROP) in zone II. Fluorescein 30-41 vascular endothelial growth factor A Homo sapiens 134-138 35109797-2 2022 The aim of this study is to predict the treatment response of anti-vascular endothelial growth factor (anti-VEGF) therapy in BRVO using semi-automated quantified fluorescein angiography (FA) features. Fluorescein 162-173 vascular endothelial growth factor A Homo sapiens 67-101 35109797-2 2022 The aim of this study is to predict the treatment response of anti-vascular endothelial growth factor (anti-VEGF) therapy in BRVO using semi-automated quantified fluorescein angiography (FA) features. Fluorescein 162-173 vascular endothelial growth factor A Homo sapiens 108-112 33948533-1 2021 Background and purpose: Randomised-controlled clinical trials (the ANCHOR and MARINA) examined the intravitreal anti-vascular endothelial growth factor (anti-VEGF) efficacy for eyes having fluorescein angiographic classic and occult (OCC) neovascular lesions. Fluorescein 189-200 vascular endothelial growth factor A Homo sapiens 117-151 35141247-0 2021 Different Types of Hyperfluorescence Observed in Post Anti-VEGF Fluorescein Angiographic Patterns in Retinopathy of Prematurity Patients. Fluorescein 64-75 vascular endothelial growth factor A Homo sapiens 59-63 35141247-1 2021 Purpose: To demonstrate that the demographic and treatment characteristics of retinopathy of prematurity (ROP) eyes showed different types of hyperfluorescence in fluorescein angiography (FA) initially treated with anti-vascular endothelial growth factor (VEGF) agents. Fluorescein 163-174 vascular endothelial growth factor A Homo sapiens 220-254 35141247-1 2021 Purpose: To demonstrate that the demographic and treatment characteristics of retinopathy of prematurity (ROP) eyes showed different types of hyperfluorescence in fluorescein angiography (FA) initially treated with anti-vascular endothelial growth factor (VEGF) agents. Fluorescein 163-174 vascular endothelial growth factor A Homo sapiens 256-260 34649253-2 2022 PATIENTS AND METHODS: In this retrospective cohort study, 22 eyes of 22 patients with anti-VEGF-resistant chronic CSC, showing focal or diffuse foveal leakages on fundus fluorescein angiography (FFA), were included. Fluorescein 170-181 vascular endothelial growth factor A Homo sapiens 91-95 33948533-1 2021 Background and purpose: Randomised-controlled clinical trials (the ANCHOR and MARINA) examined the intravitreal anti-vascular endothelial growth factor (anti-VEGF) efficacy for eyes having fluorescein angiographic classic and occult (OCC) neovascular lesions. Fluorescein 189-200 vascular endothelial growth factor A Homo sapiens 158-162 32394732-1 2020 Purpose: To describe the optical coherence tomography angiography (OCTA) features of active inflammatory choroidal neovascularization (CNV) and characterize the early responses of anti-vascular endothelial growth factor (VEGF) treatment for inflammatory CNV.Methods: OCT angiography images of inflammatory CNV were acquired and analyzed using the RTVue XR Avanti with AngioVue at baseline as well as fluorescein angiography and spectral-domain optical coherence tomography (SD-OCT). Fluorescein 400-411 vascular endothelial growth factor A Homo sapiens 221-225 33613250-4 2021 A 74-year-old Japanese man diagnosed with retinal angiomatous proliferation by fluorescein angiography and indocyanine green angiography was treated with intravitreal anti-VEGF injection. Fluorescein 79-90 vascular endothelial growth factor A Homo sapiens 172-176 32058830-2 2020 Reports that did not compare UME findings before and after the therapy, using either OCT or fluorescein angiography, were excluded.Results: Case series that analyzed the efficacy of intravitreal anti-VEGF agents showed modest, short-term benefit. Fluorescein 92-103 vascular endothelial growth factor A Homo sapiens 200-204 30664126-9 2019 CONCLUSION: After anti-vascular endothelial growth factor injections, the improvement in the DRSS score based on color fundus photographs can occur without retinal reperfusion on ultra-wide-field fluorescein angiography. Fluorescein 196-207 vascular endothelial growth factor A Homo sapiens 23-57 28291070-5 2019 As a result of the fluorescein angiography findings, we believe ATRA-mediated upregulation of vascular endothelial growth factor may be the etiology of the NVD. Fluorescein 19-30 vascular endothelial growth factor A Homo sapiens 94-128 28377846-15 2017 TRANSLATIONAL RELEVANCE: Fluorescein angiography can define focal and diffuse subtypes of diabetic macular edema and these may respond differently to anti-VEGF treatment. Fluorescein 25-36 vascular endothelial growth factor A Homo sapiens 155-159 29727107-6 2016 In the diabetic macular edema and retinal vein occlusion group, the con- centration of vascular endothelial growth factor in aqueous humor positively correlated with the extent of non-perfusion areas measured on fluorescein angiograms (Rs = + 0.45, p = 0.02;). Fluorescein 212-223 vascular endothelial growth factor A Homo sapiens 87-121 28176934-1 2017 PURPOSE: The aim of this study is to report peripheral reperfusion of ischemic areas of the retina on ultra-widefield fluorescein angiography (UWFA) following anti-vascular endothelial growth factor (VEGF) intravitreal injections in patients treated for diabetic retinopathy. Fluorescein 118-129 vascular endothelial growth factor A Homo sapiens 159-198 28176934-1 2017 PURPOSE: The aim of this study is to report peripheral reperfusion of ischemic areas of the retina on ultra-widefield fluorescein angiography (UWFA) following anti-vascular endothelial growth factor (VEGF) intravitreal injections in patients treated for diabetic retinopathy. Fluorescein 118-129 vascular endothelial growth factor A Homo sapiens 200-204 18783494-13 2008 Bevacizumab, a pan VEGF A antibody, was found to reduce both the proliferation of endothelial cells in CNV membranes and the propensity to leak in fluorescein angiograms. Fluorescein 147-158 vascular endothelial growth factor A Homo sapiens 19-25 24909062-0 2014 Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies. Fluorescein 0-11 vascular endothelial growth factor A Homo sapiens 106-110 24698606-0 2014 Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy. Fluorescein 8-19 vascular endothelial growth factor A Homo sapiens 69-73 23185181-0 2012 Choroidal neovascularization regression on fluorescein angiography after VEGF blockade. Fluorescein 43-54 vascular endothelial growth factor A Homo sapiens 73-77 21233856-2 2011 Fluorescein-labeled short-hairpin (sh)RNA plasmids together and separately targeting VEGF, C-myc, Survivin and hTERT were built and respectively called plasmid-shVEGF-shC-myc-shSurvivin-shhTERT, plasmid-shVEGF, plasmid-shC-myc, plasmid-shSurvivin, plasmid-shhTERT. Fluorescein 0-11 vascular endothelial growth factor A Homo sapiens 85-89 20237252-7 2010 After laser injury, mice were injected either intraocularly or subcutaneously with recombinant human VEGF-A(165)b. Intraocular injection of rhVEGF-A(165)b gave a pronounced dose-dependent inhibition of fluorescein leakage, with an IC(50) of 16 pg/eye, neovascularization (IC(50), 0.8 pg/eye), and lesion as assessed by histologic staining (IC(50), 8 pg/eye). Fluorescein 202-213 vascular endothelial growth factor A Homo sapiens 101-107 20452027-10 2010 CONCLUSIONS: Spectral-domain optical coherence tomography seems more likely than TD-OCT to detect abnormalities when fluorescein leakage from CNV is detected after anti-VEGF therapy. Fluorescein 117-128 vascular endothelial growth factor A Homo sapiens 169-173 12560209-3 2003 Exposure to 1 nM VEGF transiently increased apparent permeability to 2.3, 3.3, and 6.2 times their baseline values for sodium fluorescein, alpha-lactalbumin, and BSA, respectively, within 30 s, and all returned to control within 2 min. Fluorescein 119-137 vascular endothelial growth factor A Homo sapiens 17-21 16977340-3 2007 Before administration of the VEGF antibody leakage was distinctly seen on fluorescein angiography, which did not appear on examination after the treatment. Fluorescein 74-85 vascular endothelial growth factor A Homo sapiens 29-33 15965177-4 2005 RESULTS: One transgenic line expressing low hVEGF levels showed mild clinical changes such as focal fluorescein leakage, microaneurysms, venous tortuosity, capillary non-perfusion and minor neovascularisation, which remained stable up to 3 months postnatal. Fluorescein 100-111 vascular endothelial growth factor A Homo sapiens 44-49 17175539-5 2007 Recently, a polyamide-fluorescein conjugate targeted to the hypoxia response element (HRE) was found to inhibit vascular endothelial growth factor (VEGF) expression in cultured HeLa cells. Fluorescein 22-33 vascular endothelial growth factor A Homo sapiens 112-146 17175539-5 2007 Recently, a polyamide-fluorescein conjugate targeted to the hypoxia response element (HRE) was found to inhibit vascular endothelial growth factor (VEGF) expression in cultured HeLa cells. Fluorescein 22-33 vascular endothelial growth factor A Homo sapiens 148-152 15509618-5 2005 Brain swelling was not influenced in VEGF-overexpressing animals, while sodium fluorescein extravasation was moderately increased, suggesting that VEGF induces a mild blood-brain barrier leakage. Fluorescein 72-90 vascular endothelial growth factor A Homo sapiens 147-151 12954624-4 2003 The fluorescein-labeled SP5.2 specifically bound to VEGF-stimulated primary human cerebral endothelial cells (HCECs), whereas non-stimulated HCECs, as well as human neuroblastoma cells (ShyY) did not show any interaction with the peptide. Fluorescein 4-15 vascular endothelial growth factor A Homo sapiens 52-56